chang tp
number share mn
price month
disappoint data studi
opdivo
event close juli us time bristol-my squibb
anti-cancer agent opdivo antibodi plu low-dos yervoy non-
small cell lung cancer nsclc part trial combin
met co-primari endpoint overal surviv os first-lin nsclc
patient whose tumor express part studi howev
meet pre-specifi primari endpoint os regardless
statu wake announc ono pharmaceut issu
press releas prior morn trade juli japan time
studi
part result disappoint result part studi
view opportun opdivo close gap merck keytruda
preced market howev primari endpoint os
met lung cancer highest mortal rate among cancer
larg proport opdivo sale use treatment nsclc
base latest result chang domest
sale estim opdivo think opdivo struggl
catch keytruda lung cancer market
price rel chart measur perform
topix close
spot exchang rate
valuat metric
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
issuanc retir stock
net chang cash
number share mn
compani mention price
